JOURNAL OF ONCOLOGY PRACTICE, vol.8, no.3, pp.141-143, 2012 (SCI-Expanded)
Article / Article
JOURNAL OF ONCOLOGY PRACTICE
Science Citation Index Expanded (SCI-EXPANDED), Emerging Sources Citation Index (ESCI), Scopus
Hacettepe University Affiliated:
Purpose: Rituximab is a chimeric anti-CD20 monoclonal antibody. We aimed to explore the safety and tolerability of rapid infusion rituximab, (over 90 minutes) in patients with non-Hodgkin's lymphoma at Hacettepe University Department of Medical Oncology.